Folic acid and B12 supplementation improves survival of elderly hemodialysis patients

Folic Acid: Properties, Medical Uses and Health Benefits

Volumn , Issue , 2012, Pages 191-209

  Righetti, Marco ^a  

^a Department of Pediatrics   (Italy)

Author keywords

Bone disease.; Cardiovascular disease; Dialysis; Folic acid; Homocysteine; Vitamin b12

Indexed keywords

EID: 84863749294     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (57)

1. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wetzels JF, Rosendaal FR, Dekker FW. Cardiovascular and non cardiovascular mortality among patients starting dialysis. JAMA. 2009 Oct 28;302(16):1782-9.
2. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000, 356: 147-52.
3. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod A, Vanholder R, Walker R, Wang H. The burden of kidney disease: improving global outcomes. Kidney Int 2004, 66: 1310-4.
4. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GH. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J. Am. Med. Assoc. 1997, 277: 1775-81.
5. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br. Med. J. 2002, 325: 1202-8.
6. Fissell RB, Bragg-Gresham JL, Gillespie BW, Goodkin DA, Bommer J, Saito A, Akiba T, Port FK, Young EW. International variation in vitamin prescription and association with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. 2004, 44: 293-9.
7. Kalantar-Zadeh K, Block G, Humphreys MH, Mcallister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J. Am. Soc. Nephrol. 2004, 15: 442-53.
8. Wrone EM, Hornberger JM, Zehnder JL, Mccann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J. Am. Soc. Nephrol 2004, 15: 420-6.
9. Oishi K, Nagake Y, Yamasaki H, Fukuda S, Ichikawa H, Ota K, Makino H. The significance of serum homocysteine levels in diabetic patients on hemodialysis. Nephrol Dial Tranplant 2000; 15: 851-5.
10. Ducloux D, Klein A, Kazory A, Devillard N, Chalopin JM. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int 2006, 69: 331-5.
11. Righetti M, Serbelloni P, Milani S, Ferrario GM. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006, 24: 379-86.
12. Suliman M, Stenvinkel P, Qureshi AR, Kalantar-Zadeh K, Barany P, Heimbürger O, Vonesh EF, Lindholm B. The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. Nephrol Dial Transplant 2007, 22: 209-17
13. Yap S, Boers GHJ, Wilcken B, Wilcken DEL, Brenton DP, Lee PJ, Walter JH, Howard PM, Naughten ER. Arterioscler Thromb. Vasc. Biol. 2001, 21: 2080-5.
14. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, Friedman JM. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006, 13: 1335-43.
15. Bazzano LA, Reynolds K, Holder KN, He Y. Effect of folic acid supplementation on risk of cardiovascular diseases. JAMA 2006, 296: 2720-6.
16. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291: 565-75.
17. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin intervention for stroke prevention trial. An efficacy analysis. Stroke 2005, 36: 2404-9.
18. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Nordrehaug JE, Arnesen E, Rasmussen K, NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 2006, 354: 1578-88.
19. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Poque J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 2006, 354: 1567-77.
20. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007, 369: 1876-82.
21. Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, Xu X, Wang X. Folic acid therapy and cardiovascular disease in end-stage renal disease and advanced chronic kidney disease: a meta-analysis. Clin J. Am. Soc. Nephrol. 2011; 6(3): 482-488.
22. Righetti M, Ferrario GM, Milani S, Serbelloni P, La Rosa L, Uccellini M, Sessa A. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med. Sci. Monit. 2003; 9: PI19-PI24.
23. Heinz J, Kropf S, Domrose U, Westphal S, Borucki K, Luley C, Neumann KH, Dierkes J. B Vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010; 121: 1432-1438.
24. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, Atkins RC, Nicholls K, Fraenkel M, Hutchison BG, Walker R, McNeil JJ. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure. JACC 2006, 47: 1108-16.
25. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end stage renal disease: a randomized controlled trial. JAMA 2007; 298: 1163-1170.
26. Vianna AC, Mocelin AJ, Matsuo T, Morais-Filho D, Largura A, Delfino VA, Soares AE, Matni AM. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial. Int. 2007; 11: 210-216.
27. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end stage renal disease. J. Am. Soc. Nephrol 2004; 15: 420-426.
28. Righetti M, Ferrario G, Serbelloni P, Milani S, Tommasi A. Associazione diretta tra l'uso di vitamine B e la sopravvivenza dei pazienti anziani in emodialisi. Giornale Italiano di Nefrologia 2010; 27 (S51): S33
29. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kideny Int 2006; 70 (7): 1358-1366.
30. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP. Homocysteine as a predictive factor for hip fracture in older persons. N. Engl. J. Med. 2004; 350: 2042-2049.
31. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG. Homocysteine levels and the risk of osteoporotic fractures. N. Engl. J. Med. 2004; 350: 2033-2041.
32. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005; 293: 1082-1088.
33. Righetti M, Ferrario G, Serbelloni P, Milani S, Dossi C, Tommasi A. High bone and cardiovascular morbidity in folate-resistant hemodialysis patients. Nephrol Dial Transplant Plus 2008; 1(S2): ii211 (MO002).
34. Righetti M. Protective effect of vitamin B therapy on bone and cardiovascular disease. Recent Patents on Cardiovascular Drug Discovery 2009; 4: 37-44.
35. Righetti M, Filiberti O, Ranghino A, G Ferrario, S Milani, P Serbelloni, GE Guida, A Tommasi. Internal haemodiafiltration vs. low-flux bicarbonate dialysis: results from a long term prospective study. Int J Artif Organs 2010 Nov; 33(11): 796-802.
36. Arnadottir M, Berg AL, Hegbrant J, Hultberg B. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol. Dial Transplant 1999, 14: 142-6.
37. Arnadottir M, Wingren K, Hultberg B, Hegbrant J. The postdialytic rise in the plasma total homocysteine concentration is delayed. Blood Purif 2002, 20: 334-7.
38. House AA, Wells GA, Donnelly JG, Nadler SP, Hèbert PC. Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 2000, 15: 1029-34.
39. Mudge DW, Rogers R, Hollett P, Law B, Reiger K, Petrie JJB, Price L, Johnson DW, Campbell SB, Isbel NM, Sullivan M, Hawley CM. Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance. Nephrol Dial Transplant 2005, 20: 2178-85.
40. Van Telligen A, Grooteman MP, Bartels PC, Van Limbeek J, Van Guldener C, Wee PM, Nube MJ. Long-term reduction of plasma homocysteine levels by super-flux dialysers in hemodialysis patients. Kidney Int. 2001, 59: 342-7.
41. De Vriese AS, Langlois M, Bernard D, Geerolf I, Stevens L, Boelaert JR, Schurgers M, Matthys E. Effect of dialyser membrane pore size on plasma homocysteine levels in hemodialysis patients. Nephrol. Dial Transplant 2003, 18: 2596-600.
42. Galli F, Benedetti S, Buoncristiani U, Piroddi M, Conte C, Canestrai F, Buoncristiani E, Floridi A. The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int. 2003, 64: 748-55.
43. Righetti M, Ferrario GM, Serbelloni P, Milani M, Tommasi A. Homocysteine reduction rate in internal haemodiafiltration: a comparison with other mixed dialysis therapies. Nephrol. Dial Transplant 2006, 21: 2034-5.
44. Beerenhout C, Luik AJ, Jeuken-Mertens SGJ, Bekers O, Menheere P, Hover L, Klaassen L, van der Sande FM, Cheriex EC, Meert N, Leunissen KM, Kooman JP. Pre-dilution on-line haemofiltration vs low-flux haemodialysis: a randomised prospective study. Nephrol. Dial. Transplant 2005, 20: 1155-63.
45. Friedman AN, Bostom AG, Levy AS, Rosenberg IH, Selhub J, Pierratos A. Plasma total homocysteine levels among patients undergoing nocturnal vs standard hemodialysis. J. Am. Soc. Nephrol 2002, 13: 265-8.
46. Moustapha A, Gupta A, Robinson K, Arheart K, Jacobsen DW, Schreiber MJ, Dennis VW. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999, 55: 1470-5.
47. Righetti M, Tommasi A, Lagona C, La Rosa L, Uccellini M, Sessa A. Effective homocysteine-lowering vitamin B treatment in peritoneal dialysis patients. Perit Dial Int.2004, 24: 373-7.
48. Johnson DW, Kay TD, Vesey DA, Isbel N, Campbell SB, Hawley CM. Peritoneal homocysteine clearance is inefficient in peritoneal dialysis patients. Perit Dial Int. 2000, 20: 766-71.
49. Homocysteine Lowering Trialists Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analyses of randomised trials. BMJ 1998, 316: 894-8.
50. Sunder-Plassmann G, Födinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, Enzenberger B, Janata O, Winkelmayer WC, Paul G, Auinger M, Barnas U, Hörl WH. Effect of high dose folic acid therapy on Hyperhomocysteinemia in hemodialysis patients: results of the Vienna Multicenter Study. J. Am. Soc. Nephrol. 2000, 11: 1106-16.
51. Van Guldener C, Janssen MJFM, Lambert J, ter Wee PM, Jakobs C, Donker AJ, Stehouwer CD. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinemia in hemodialysis patients. Nephrol Dial Transplant 1998, 13: 106-12.
52. Ducloux D, Aboubakr A, Motte G, Toubin G, Fournier V, Chalopin JM, Drueke T, Massy ZA. Hyperhomocysteinemia therapy in hemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. Nephrol. Dial Transplant 2002, 17: 865-70.
53. Institute of Medicine. Dietary reference intakes for thiamine, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington DC, National Academy Press 2000, 150-95.
54. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004, 109: 369-74.
55. Thaha M, Yogiantoro M, Tomino Y. Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease. Clin. Drug Investig 2006, 26: 195-202.
56. Friedman AN, Bostom AG, Laliberty P, Selhub J, Shemin D. The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomised, controlled study. Am. J. Kidney Dis. 2003, 41: 442-6.
57. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. Circulation 2003, 107: 992-5.